Overview
- The round was led by New Rhein Healthcare Investors, Andera Partners and Omega Funds, with Sanofi Capital, Kurma Partners and Avego BioScience Capital participating.
- Andera’s Jan Van den Bossche and Omega Funds’ Claudio Nessi are joining the board of directors.
- Proceeds will fund Phase 2 development of ALV-100, a bifunctional GIPR antagonist and GLP-1 receptor agonist designed for durable weight loss with less frequent dosing.
- Alveus is preparing IND submissions for early programs including ALV-200, a selective amylin receptor 3 peptide agonist described as entering IND‑enabling or regulatory filing stages.
- Headquartered in Philadelphia with R&D in Copenhagen, the company is led by CEO Raj Kannan and senior executives with prior obesity and metabolic drug experience at Novo Nordisk and Eli Lilly.